Pharmacology is fast becoming an information industry. The search for a new drug is increasingly a search for information about how a molecule of our design will interact with different arrays of molecules. The FDA has spent the last 30 years pondering how, if at all, molecular science might be shoehorned into the clinical trial protocols that Washington first used over 70 years ago and formalized in licensing rules developed in the 1960s. The regulatory system is now frozen in the headlights.